TMhuCART19 IL18 - Kite Pharma
Alternative Names: Anti-CD19 antigen/IL-18 expressing autologous CAR-T expressing IL-18 cell therapy; huCART19-IL18 cells; TmCD19-IL18 CAR T cells; TMhuCART19-IL18Latest Information Update: 30 Nov 2023
At a glance
- Originator Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 09 Nov 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT05989204)
- 14 Aug 2023 University of Pennsylvania in collaboration with Kite pharma plans a phase I trial for Non Hodgkin Lymphoma (Second-line therapy or greater) in October 2023 (IV, Infusion) (NCT05989204)
- 14 Aug 2023 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV) prior to August 2023 (NCT05989204)